[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100562658":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":41,"centralContacts":45,"locations":51,"responsibleParty":71,"collaborators":73,"id":77,"slug":78,"hasResults":79,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":10,"eligibilityCriteria":83,"healthyVolunteers":79,"sex":84,"minAge":85,"maxAge":10,"enrollmentInfo":86,"targetDuration":10,"studyType":89,"phases":10,"briefSummary":90,"conditions":91,"keywords":96,"overallStatus":53,"whyStopped":10,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":107},{"fullName":5,"class":6},"University of California, San Francisco","OTHER",[8,16],{"label":9,"type":10,"description":11,"interventionNames":12},"Cohort A: Non-investigational Radiation therapy",null,"Participants will have tumor tissue collected at screening and blood samples (approximately 20ml x 3) will be obtained during non-investigational, standard of care radiation and after care for up to 2 years.",[13,14,15],"Procedure: Blood Specimen Collection","Procedure: Tumor Tissue Collection","Other: Medical Record Review",{"label":17,"type":10,"description":18,"interventionNames":19},"Cohort B: Non-investigational Surgery","Participants will have tumor tissue collected at screening and blood samples (approximately 20ml x 3) will be obtained during non-investigational, standard of care surgery and after care for up to 2 years.",[13,14,15],[21,29,35],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"PROCEDURE","Blood Specimen Collection","Approximately 20 mL of peripheral blood (10 mL per tube, x 3 Streck tubes) will be drawn at each time point",[9,17],[27,28],"Blood Specimen","Biospecimen collection",{"type":22,"name":30,"description":31,"armGroupLabels":32,"otherNames":33},"Tumor Tissue Collection","Formalin-fixed paraffin embedded tumor tissue samples (tissue blocks of 12 x 10 millimeter (mm) unstained slides) derived from biopsy or surgical resection will be collected at screening",[9,17],[34,28],"Tissue Specimen",{"type":6,"name":36,"description":37,"armGroupLabels":38,"otherNames":39},"Medical Record Review","Medical records will be reviewed to collect standard of care p16 staining by immunohistochemistry and\u002For high-risk human papillomavirus (HPV) DNA or RNA testing that is performed as part of standard of care",[9,17],[40],"Chart Review",[42],{"name":43,"affiliation":5,"role":44},"Jason W Chan, MD","PRINCIPAL_INVESTIGATOR",[46],{"name":47,"role":48,"phone":49,"phoneExt":10,"email":50},"Sonia Contreras Martinez","CONTACT","415-514-6427","sonia.contrerasmartinez@ucsf.edu",[52],{"facility":5,"status":53,"city":54,"state":55,"zip":56,"country":57,"countryCode":58,"cosmosGeoPoint":59,"geoPoint":64,"contacts":65},"RECRUITING","San Francisco","California","94143","United States","US",{"type":60,"coordinates":61},"Point",[62,63],-122.41942,37.77493,{"lat":63,"lon":62},[66,67,70],{"name":47,"role":48,"phone":49,"phoneExt":10,"email":10},{"name":50,"role":48,"phone":68,"phoneExt":10,"email":69},"877-827-3222","cancertrials@ucsf.edu",{"name":43,"role":44,"phone":10,"phoneExt":10,"email":10},{"type":72,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[74],{"name":75,"class":76},"Haystack Oncology, Inc.","UNKNOWN","100562658","tumor-informed-ctdna-testing-for-mrd-following-treatment-of-squamous-cell-carcinoma-100562658",false,"NCT06606028","Tumor-Informed ctDNA Testing for MRD Following Treatment of Squamous Cell Carcinoma","Tumor-informed ctDNA Testing for Minimal Residual Disease Monitoring Following Curative-intent Treatment of Squamous Cell Carcinoma of the Head and Neck.","Inclusion Criteria:\n\n1. Participants must have histologically or cytologically confirmed squamous cell carcinoma of the head and neck mucosa and skin.\n2. Participants must be age \\>=18 years.\n3. Participants must be planning to receive curative-intent surgery or radiation-based treatment as part of standard of care treatment.\n4. Participants must have the ability to understand and the willingness to sign a written informed consent document.\n\nExclusion Criteria:\n\n1\\. Contraindication to phlebotomy for removal of 20 mL of peripheral blood each time point (up to 300 mL total over 15 time points).","ALL","18 Years",{"count":87,"type":88},250,"ESTIMATED","OBSERVATIONAL","This is a single-center, non-interventional, observational study that evaluates the correlation of circulating tumor DNA (ctDNA) testing to cancer relapse for participants with squamous cell carcinomas (HNC) of the head and neck mucosa and skin after curative-intent primary radiation or surgery.",[92,93,94,95],"Squamous Cell Carcinoma of Head and Neck","Squamous Cell Carcinoma Head and Neck Cancer (HNSCC)","Squamous Cell Carcinoma of Skin","Cutaneous Squamous Cell Carcinoma (CSCC)",[97],"ctDNA","2025-12-04",{"date":100,"type":101},"2025-12-12","ACTUAL",{"date":103,"type":101},"2024-10-09",{"date":105,"type":88},"2029-12-30",{"name":5,"class":6},1]